Disposition kinetics of a dipeptide ester prodrug of acyclovir and its metabolites following intravenous and oral administrations in rat
- 21 August 2009
- journal article
- research article
- Published by Taylor & Francis Ltd in Clinical Research and Regulatory Affairs
- Vol. 26 (3), 65-72
- https://doi.org/10.1080/10601330903200684
Abstract
The objective of this work was to study the disposition kinetics of valine-valine–acyclovir (VVACV), a dipeptide ester prodrug of acyclovir following intravenous and oral administrations in rat. A validated LC-MS/MS analytical method was developed for the analysis VVACV, Valine-Acyclovir (VACV), and Acyclovir (ACV) using a linear Ion Trap Quadrupole. ACV was administered orally for comparison purpose. In the VVACV group, both blood and urine samples and in the ACV group only blood samples were collected. All the samples were analyzed using LC-MS/MS. The LLOQ for ACV, VACV, and VVACV were 10, 10, and 50 ng/ml, respectively. Relevant pharmacokinetic parameters were obtained by non-compartmental analyses of data with WinNonlin. Following i.v. administration of VVACV, AUC0-inf (min*μM) values for VVACV, VACV, and ACV were 55.06, 106, and 466.96, respectively. The AUC obtained after oral administration of ACV was 178.8. However, following oral administration of VVACV, AUC0-inf values for VACV and ACV were 89.28 and 810.77, respectively. Thus the exposure of ACV obtained following oral administration of VVACV was almost 6-fold higher than ACV. This preclinical pharmacokinetic data revealed that VVACV has certainly improved the oral bioavailability of ACV and is an effective prodrug for oral delivery of ACV.Keywords
This publication has 21 references indexed in Scilit:
- Oral Bioavailability Enhancement of Acyclovir by Self-Microemulsifying Drug Delivery Systems (SMEDDS)Drug Development and Industrial Pharmacy, 2007
- Renal Tubular Drug TransportersNephron Physiology, 2006
- Renal tubular transporters and antiviral drugs: an updateAIDS, 2005
- Pharmacokinetics of Novel Dipeptide Ester Prodrugs of Acyclovir after Oral Administration: Intestinal Absorption and Liver MetabolismThe Journal of pharmacology and experimental therapeutics, 2004
- The proton oligopeptide cotransporter family SLC15 in physiology and pharmacologyPflügers Archiv - European Journal of Physiology, 2004
- Synthesis and characterization of novel dipeptide ester prodrugs of acyclovirSpectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2003
- Relation between herpes simplex viruses and human immunodeficiency virus infections.Archives of Dermatology, 1999
- Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humansAntimicrobial Agents and Chemotherapy, 1995
- Metabolism and pharmacokinetics of a double prodrug of ganciclovir in the rat and monkey.1995
- Review of research leading to new anti-herpesvirus agents in clinical development: Valaciclovir hydrochloride (256u, the L-valyl ester of acyclovir) and 882c, a specific agent for varicella zoster virusJournal of Medical Virology, 1993